Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a
Authors:
- 24 November 2010
- journal article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 18 (8) , 595-600
Abstract
Summary. The optimal duration of treatment and expected response rate for hepatitis C virus genotype (HCV‐6)‐infected patients have not been determined. Our aims were to determine the treatment outcome with pegylated interferon (PEG‐IFN) plus ribavirin for HCV‐6a‐infected patients at Southwest Hospital and assess the association of the on‐treatment virological response with the sustained virological response (SVR). Medical records were reviewed retrospectively. Twenty‐two HCV‐6a‐infected patients were treated for 24 weeks, and 21 (95.5%) achieved an early virological response (EVR), 20 (90.9%) an end‐of‐treatment response (ETR) and 18 (81.8%) a SVR. However, only 18 of the 22 HCV‐6a‐infected patients were tested for serum HCV RNA level at week 4 of treatment and 15 (83.3%) achieved a rapid virological response (RVR). The rates of SVR, RVR, EVR and ETR in these patients were all similar to those in HCV‐2/3 treated for 24 weeks and higher than those in HCV‐1b‐infected patients treated for 48 weeks. A lower relapse rate (10.0%) was seen in HCV‐6a compared with HCV‐2/3 (12.5%) or HCV‐1b‐infected patients (23.3%). The positive predictive values of RVR and EVR for HCV‐6a were comparable with those for HCV‐2/3‐infected patients (86.7%vs 90.9%, P = 0.683 and 85.7%vs 86.8%, P = 0.904, respectively). Of the 3 HCV‐6a‐infected patients who did not achieve a RVR, 2 achieved an EVR and went on to achieve a SVR. The patient who did not achieve an EVR did not achieve a SVR. In summary, our results indicate that 24 weeks of PEG‐IFN plus ribavirin can effectively treat patients with HCV‐6a chronic infection.Keywords
This publication has 21 references indexed in Scilit:
- Review article: the role of rapid virological response in determining treatment duration for chronic hepatitis CAlimentary Pharmacology & Therapeutics, 2010
- Response to pegylated interferon and ribavirin in Asian American patients with Chronic hepatitis C genotypes 1 vs 2/3 vs 6Journal of Viral Hepatitis, 2009
- Molecular epidemiology of HCV genotypes among injection drug users in Taiwan: Full‐length sequences of two new subtype 6w strains and a recombinant form_2b6wJournal of Medical Virology, 2009
- Genetic variation in IL28B and spontaneous clearance of hepatitis C virusNature, 2009
- The Evolution of the Major Hepatitis C Genotypes Correlates with Clinical Response to Interferon TherapyPLOS ONE, 2009
- What is the safe duration of therapy for patients infected with HCV genotype 6?Nature Clinical Practice Gastroenterology & Hepatology, 2008
- Chronic Hepatitis C Virus Genotype 6 Infection: Response to Pegylated Interferon and RibavirinThe Journal of Infectious Diseases, 2008
- Identification of hepatitis C virus genotype 6 in Korean patients by analysis of 5′ untranslated region using a matrix assisted laser desorption/ionization time of flight‐based assay, restriction fragment mass polymorphismJournal of Medical Virology, 2008
- The unique HCV genotype distribution and the discovery of a novel subtype 6u among IDUs co‐infected with HIV‐1 in Yunnan, ChinaJournal of Medical Virology, 2008
- Interferon and Ribavirin Therapy for Chronic Hepatitis C Virus Genotype 6: A Comparison with Genotype 1The Journal of Infectious Diseases, 2003